2 months Travere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & Company MarketBeat
Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $9.00 to $27.00 in a research report on Monday.
Nasdaq 100 · Science · Wells Fargo&Co (WFC)
X